This page is intended for UK health professionals only. If you are a patient / carer, please click here.
If you are a member of the general public, please click here.
Indications: Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with Von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.3
References
- Lissitchkov TJ, Buevich E, et al. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with Von Willebrand disease (SWIFT-VWD study). Blood Coagulation and Fibrinolysis. 2017;28(2):152–162.
- Auerswald G, Khayat CD, et al. Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVII Concentrate (Formulation V) in Pediatric Patients with Von Willebrand Disease (SWIFTLY–VWD Study). Journal of Blood Medicine. 2020;11:213–225.
- CSL Berhing UK Limited. Voncento Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447 405.